SCHEMBL1320719

SCHEMBL1320719

COc1cc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.53
PGR P06401 2/20 0.50
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
HTR6 P50406 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
TP53 P04637 2/20 0.48
CYP17A1 P05093 2/20 0.47
FABP4 P15090 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13658714 0.93 SMN1; SMN2 (0.47) ACLYPGRPSEN1PSEN2APH1B
SCHEMBL8752454 0.83 MEN1 (0.55) MEN1KMT2AHTTSMN1; SMN2MAPT
SCHEMBL2055431 0.81 HCRTR1 (0.59) ACLYPGRPSEN1PSEN2APH1B
SCHEMBL2055428 0.76 KEAP1 (0.67) ACLYMEN1KMT2AHTTSMN1; SMN2
SCHEMBL29561264 0.74 ACLY (0.62) ACLYPGRMEN1KMT2AHTT
SCHEMBL2055426 0.74 ACLY (0.58) ACLYMEN1KMT2AHTTSMN1; SMN2
SCHEMBL10676915 0.73 PDE4A (0.44) HTR6MEN1KMT2AMAPTALDH1A1
SCHEMBL28254216 0.73 NQO1 (0.46) SMN1; SMN2MAPTCYP17A1ALDH1A1LMNA
SCHEMBL3762452 0.72 PGR (0.74) ACLYPGRPSEN1PSEN2APH1B
SCHEMBL12115604 0.72 KEAP1 (0.52) MEN1KMT2ASMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 ACLY 1173/4885PGR 2120/4885PSEN1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.